LABELS · a09d3635-1735-4ac9-884e-5c49897da6f5

Ilaris

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-06-08
Captured: 2026-09-09T23:37:54.830918+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

1 INDICATIONS AND USAGE ILARIS is an interleukin-1β blocker indicated for the treatment of: • Periodic Fever Syndromes ( 1.1 ): - Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold Auto-inflammatory Syndrome (FCAS) ◾ Muckle-Wells Syndrome (MWS) - Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients - Hyperimmunoglobulin D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients - Familial Mediterranean Fever (FMF) in adult and pediatric patients • Active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older ( 1.2 ) • Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate ( 1.3 ) 1.1 Periodic Fever Syndromes ILARIS ® (canakinumab) is an interleukin-1β (IL-1β) blocker indicated for the treatment of the following autoinflammatory Periodic Fever Syndromes: Cryopyrin-Associated Periodic Syndromes (CAPS) ILARIS is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and pediatric patients 4 years of age and older, including: Familial Cold Autoinflammatory Syndrome (FCAS) Muckle-Wells Syndrome (MWS) Tumor Necrosis Factor Receptor (TNF) Associated Periodic Syndrome (TRAPS) ILARIS is indicated for the treatment of Tumor Necrosis Factor (TNF) Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients. Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) ILARIS is indicated for the treatment of Hyperimmunoglobulin D (Hyper-IgD) Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients. Familial Mediterranean Fever (FMF) ILARIS is indicated for the treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients. 1.2 Still’s Disease (Adult-Onset Still’s Disease [AOSD] and Systemic Juvenile Idiopathic Arthritis [SJIA]) ILARIS is indicated for the treatment of active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older. 1.3 Gout Flares ILARIS is indicated for the symptomatic treatment of adult patients with gout flares in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.

Full extracted label fields

application numbers

BLA125319

boxed warning exact

brand names

Ilaris

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d271f3b-e4f9-4d80-8dcf-28d49123f80e

generic names

CANAKINUMAB

a09d3635-1735-4ac9-884e-5c49897da6f5

indications and usage exact

1 INDICATIONS AND USAGE ILARIS is an interleukin-1β blocker indicated for the treatment of: • Periodic Fever Syndromes ( 1.1 ): - Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold Auto-inflammatory Syndrome (FCAS) ◾ Muckle-Wells Syndrome (MWS) - Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients - Hyperimmunoglobulin D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients - Familial Mediterranean Fever (FMF) in adult and pediatric patients • Active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older ( 1.2 ) • Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate ( 1.3 ) 1.1 Periodic Fever Syndromes ILARIS ® (canakinumab) is an interleukin-1β (IL-1β) blocker indicated for the treatment of the following autoinflammatory Periodic Fever Syndromes: Cryopyrin-Associated Periodic Syndromes (CAPS) ILARIS is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and pediatric patients 4 years of age and older, including: Familial Cold Autoinflammatory Syndrome (FCAS) Muckle-Wells Syndrome (MWS) Tumor Necrosis Factor Receptor (TNF) Associated Periodic Syndrome (TRAPS) ILARIS is indicated for the treatment of Tumor Necrosis Factor (TNF) Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients. Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) ILARIS is indicated for the treatment of Hyperimmunoglobulin D (Hyper-IgD) Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients. Familial Mediterranean Fever (FMF) ILARIS is indicated for the treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients. 1.2 Still’s Disease (Adult-Onset Still’s Disease [AOSD] and Systemic Juvenile Idiopathic Arthritis [SJIA]) ILARIS is indicated for the treatment of active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older. 1.3 Gout Flares ILARIS is indicated for the symptomatic treatment of adult patients with gout flares in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.

indications and usage tables exact

is original packager

true

manufacturer names

Novartis Pharmaceuticals Corporation

matched search terms

tumor

package ndcs

0078-0734-61

product ndcs

0078-0734

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

Warnings and Precautions, Hypersensitivity Reactions ( 5.3 ) 11/2024

record type

complete_spl_indications_section_candidate

routes

SUBCUTANEOUS

rxcuis

1864324
1864326

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00500.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

BLA125319

brand names

Ilaris

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 291
end exclusive: true
exact text: 1 INDICATIONS AND USAGE ILARIS is an interleukin-1β blocker indicated for the treatment of: • Periodic Fever Syndromes ( 1.1 ): - Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold Auto-inflammatory Syndrome (FCAS) ◾ M
label id: a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start: 0

current approval status

not_reconciled

duplicate text group

dup-40c10aaa6e0e92e5a8fd

extraction review status

automated_candidate_pending_source_review

generic names

CANAKINUMAB

ind-span-8d24e3bd7d89fbe36772

label id

a09d3635-1735-4ac9-884e-5c49897da6f5

positive predicate support span

end: 69
end exclusive: true
exact text: is an interleukin-1β blocker indicated
label id: a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start: 31

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 91
end exclusive: true
exact text: 1 INDICATIONS AND USAGE ILARIS is an interleukin-1β blocker indicated for the treatment of:
label id: a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22a09d3635-1735-4ac9-884e-5c49897da6f5%22

spl effective date

2026-06-08

spl set id

7d271f3b-e4f9-4d80-8dcf-28d49123f80e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 2 · positive indication candidate

application numbers

BLA125319

brand names

Ilaris

classification reasons

inherited_predicate_from_same_label_section_requires_review
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 796
end exclusive: true
exact text: 1 INDICATIONS AND USAGE ILARIS is an interleukin-1β blocker indicated for the treatment of: • Periodic Fever Syndromes ( 1.1 ): - Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold Auto-inflammatory Syndrome (FCAS) ◾ Muckle-Wells Syndrome (MWS) - Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients - Hyperimmunoglobulin D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients - Familial Mediterranean Fever (FMF) in adult and pediatric patients • Active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older ( 1.2 ) • Gout flares in adults in whom n
label id: a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start: 0

current approval status

not_reconciled

duplicate text group

dup-27b95a6769225b1d9ab3

extraction review status

automated_candidate_pending_source_review

generic names

CANAKINUMAB

ind-span-808ce404cff3193140b5

label id

a09d3635-1735-4ac9-884e-5c49897da6f5

positive predicate support span

end: 69
end exclusive: true
exact text: is an interleukin-1β blocker indicated
label id: a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start: 31

qualifier mentions

context exact
1.1 ): - Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familia
kind
age
polarity
not_inferred
span
end
187
end exclusive
true
exact text
adults
label id
a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start
181
context exact
yopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold Auto-i
kind
age
polarity
not_inferred
span
end
200
end exclusive
true
exact text
children
label id
a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start
192
context exact
ssociated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold Auto-inflammatory Syn
kind
age
polarity
not_inferred
span
end
215
end exclusive
true
exact text
4 years of age
label id
a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start
201
context exact
sis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients - Hyperimmunoglobulin D Syndrome (HI
kind
age
polarity
not_inferred
span
end
396
end exclusive
true
exact text
adult
label id
a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start
391
context exact
Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients - Hyperimmunoglobulin D Syndrome (HIDS)/ Mevalonate Kinase
kind
age
polarity
not_inferred
span
end
419
end exclusive
true
exact text
pediatric patients
label id
a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start
401
context exact
in D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients - Familial Mediterranean Fever (FMF)
kind
age
polarity
not_inferred
span
end
504
end exclusive
true
exact text
adult
label id
a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start
499
context exact
ome (HIDS)/ Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients - Familial Mediterranean Fever (FMF) in adult and pediatric
kind
age
polarity
not_inferred
span
end
527
end exclusive
true
exact text
pediatric patients
label id
a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start
509
context exact
pediatric patients - Familial Mediterranean Fever (FMF) in adult and pediatric patients
kind
age
polarity
not_inferred
span
end
573
end exclusive
true
exact text
adult
label id
a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start
568
context exact
patients - Familial Mediterranean Fever (FMF) in adult and pediatric patients
kind
age
polarity
not_inferred
span
end
596
end exclusive
true
exact text
pediatric patients
label id
a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start
578

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 596
end exclusive: true
exact text: • Periodic Fever Syndromes ( 1.1 ): - Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold Auto-inflammatory Syndrome (FCAS) ◾ Muckle-Wells Syndrome (MWS) - Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients - Hyperimmunoglobulin D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients - Familial Mediterranean Fever (FMF) in adult and pediatric patients
label id: a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start: 92

source url

https://api.fda.gov/drug/label.json?search=id%3A%22a09d3635-1735-4ac9-884e-5c49897da6f5%22

spl effective date

2026-06-08

spl set id

7d271f3b-e4f9-4d80-8dcf-28d49123f80e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 3 · unclassified context

application numbers

BLA125319

brand names

Ilaris

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 962
end exclusive: true
exact text: and pediatric patients - Hyperimmunoglobulin D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients - Familial Mediterranean Fever (FMF) in adult and pediatric patients • Active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older ( 1.2 ) • Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated cour
label id: a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start: 397

current approval status

not_reconciled

duplicate text group

dup-77da279e179dd954a77b

extraction review status

automated_candidate_pending_source_review

generic names

CANAKINUMAB

ind-span-9d6aa8977184057a1a00

label id

a09d3635-1735-4ac9-884e-5c49897da6f5

positive predicate support span

Source null

qualifier mentions

context exact
• Active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopath
kind
age
polarity
not_inferred
span
end
638
end exclusive
true
exact text
Adult
label id
a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start
633
context exact
d Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older ( 1.2 )
kind
age
polarity
not_inferred
span
end
744
end exclusive
true
exact text
2 years of age
label id
a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start
730

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 762
end exclusive: true
exact text: • Active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older ( 1.2 )
label id: a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start: 597

source url

https://api.fda.gov/drug/label.json?search=id%3A%22a09d3635-1735-4ac9-884e-5c49897da6f5%22

spl effective date

2026-06-08

spl set id

7d271f3b-e4f9-4d80-8dcf-28d49123f80e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · risk or warning

application numbers

BLA125319

brand names

Ilaris

classification reasons

risk_or_warning_words_without_positive_predicate

clinical review status

pending

content role

risk_or_warning

context span

end: 1212
end exclusive: true
exact text: ) in adult and pediatric patients • Active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older ( 1.2 ) • Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate ( 1.3 ) 1.1 Periodic Fever Syndromes ILARIS ® (canakinumab) is an interleukin-1β (IL-1β) blocker indicated for the treatment of the following autoinflammatory Periodic Fever Syndromes: Cryopyrin-Associated P
label id: a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start: 563

current approval status

not_reconciled

duplicate text group

dup-ffdb9d28023d7f32d880

extraction review status

automated_candidate_pending_source_review

generic names

CANAKINUMAB

ind-span-e782edeccb5583da047e

label id

a09d3635-1735-4ac9-884e-5c49897da6f5

positive predicate support span

Source null

qualifier mentions

context exact
• Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and
kind
age
polarity
not_inferred
span
end
786
end exclusive
true
exact text
adults
label id
a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start
780

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 1012
end exclusive: true
exact text: • Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate ( 1.3 )
label id: a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start: 763

source url

https://api.fda.gov/drug/label.json?search=id%3A%22a09d3635-1735-4ac9-884e-5c49897da6f5%22

spl effective date

2026-06-08

spl set id

7d271f3b-e4f9-4d80-8dcf-28d49123f80e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 5 · positive indication candidate

application numbers

BLA125319

brand names

Ilaris

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1892
end exclusive: true
exact text: -inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate ( 1.3 ) 1.1 Periodic Fever Syndromes ILARIS ® (canakinumab) is an interleukin-1β (IL-1β) blocker indicated for the treatment of the following autoinflammatory Periodic Fever Syndromes: Cryopyrin-Associated Periodic Syndromes (CAPS) ILARIS is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and pediatric patients 4 years of age and older, including: Familial Cold Autoinflammatory Syndrome (FCAS) Muckle-Wells Syndrome (MWS) Tumor Necrosis Factor Receptor (TNF) Associated Periodic Syndrome (TRAPS) ILARIS is indicated for the treatment of Tumor Necrosis Factor (TNF) Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients. Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) ILARIS is indicated for the treatment of Hyperimmunoglobulin D (Hyper-IgD) Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD)
label id: a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start: 813

current approval status

not_reconciled

duplicate text group

dup-2824bce3ad3fccf2fb53

extraction review status

automated_candidate_pending_source_review

generic names

CANAKINUMAB

ind-span-003013039877a0fa41ff

label id

a09d3635-1735-4ac9-884e-5c49897da6f5

positive predicate support span

end: 1111
end exclusive: true
exact text: is an interleukin-1β (IL-1β) blocker indicated
label id: a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start: 1065

qualifier mentions

context exact
tment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and pediatric patients 4 years of age and older, including:
kind
age
polarity
not_inferred
span
end
1335
end exclusive
true
exact text
adults
label id
a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start
1329
context exact
yopyrin-Associated Periodic Syndromes (CAPS), in adults and pediatric patients 4 years of age and older, including: Familial Cold Autoinfl
kind
age
polarity
not_inferred
span
end
1358
end exclusive
true
exact text
pediatric patients
label id
a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start
1340
context exact
Periodic Syndromes (CAPS), in adults and pediatric patients 4 years of age and older, including: Familial Cold Autoinflammatory Syndro
kind
age
polarity
not_inferred
span
end
1373
end exclusive
true
exact text
4 years of age
label id
a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start
1359
context exact
ctor (TNF) Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients.
kind
age
polarity
not_inferred
span
end
1668
end exclusive
true
exact text
adult
label id
a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start
1663
context exact
Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients.
kind
age
polarity
not_inferred
span
end
1691
end exclusive
true
exact text
pediatric patients
label id
a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start
1673

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 1692
end exclusive: true
exact text: 1.1 Periodic Fever Syndromes ILARIS ® (canakinumab) is an interleukin-1β (IL-1β) blocker indicated for the treatment of the following autoinflammatory Periodic Fever Syndromes: Cryopyrin-Associated Periodic Syndromes (CAPS) ILARIS is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and pediatric patients 4 years of age and older, including: Familial Cold Autoinflammatory Syndrome (FCAS) Muckle-Wells Syndrome (MWS) Tumor Necrosis Factor Receptor (TNF) Associated Periodic Syndrome (TRAPS) ILARIS is indicated for the treatment of Tumor Necrosis Factor (TNF) Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients.
label id: a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start: 1013

source url

https://api.fda.gov/drug/label.json?search=id%3A%22a09d3635-1735-4ac9-884e-5c49897da6f5%22

spl effective date

2026-06-08

spl set id

7d271f3b-e4f9-4d80-8dcf-28d49123f80e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 6 · positive indication candidate

application numbers

BLA125319

brand names

Ilaris

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2124
end exclusive: true
exact text: Receptor (TNF) Associated Periodic Syndrome (TRAPS) ILARIS is indicated for the treatment of Tumor Necrosis Factor (TNF) Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients. Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) ILARIS is indicated for the treatment of Hyperimmunoglobulin D (Hyper-IgD) Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients. Familial Mediterranean Fever (FMF) ILARIS is indicated for the treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients. 1.2 Still’s Disease (Adult-Onset Still’s Disease [AOSD]
label id: a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start: 1493

current approval status

not_reconciled

duplicate text group

dup-47290e7f231b16025711

extraction review status

automated_candidate_pending_source_review

generic names

CANAKINUMAB

ind-span-f7763414ae120f50188b

label id

a09d3635-1735-4ac9-884e-5c49897da6f5

positive predicate support span

end: 1785
end exclusive: true
exact text: is indicated
label id: a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start: 1773

qualifier mentions

context exact
-IgD) Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients.
kind
age
polarity
not_inferred
span
end
1900
end exclusive
true
exact text
adult
label id
a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start
1895
context exact
rome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients.
kind
age
polarity
not_inferred
span
end
1923
end exclusive
true
exact text
pediatric patients
label id
a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start
1905

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 1924
end exclusive: true
exact text: Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) ILARIS is indicated for the treatment of Hyperimmunoglobulin D (Hyper-IgD) Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients.
label id: a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start: 1693

source url

https://api.fda.gov/drug/label.json?search=id%3A%22a09d3635-1735-4ac9-884e-5c49897da6f5%22

spl effective date

2026-06-08

spl set id

7d271f3b-e4f9-4d80-8dcf-28d49123f80e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 7 · positive indication candidate

application numbers

BLA125319

brand names

Ilaris

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2268
end exclusive: true
exact text: HIDS)/Mevalonate Kinase Deficiency (MKD) ILARIS is indicated for the treatment of Hyperimmunoglobulin D (Hyper-IgD) Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients. Familial Mediterranean Fever (FMF) ILARIS is indicated for the treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients. 1.2 Still’s Disease (Adult-Onset Still’s Disease [AOSD] and Systemic Juvenile Idiopathic Arthritis [SJIA]) ILARIS is indicated for the treatment of active Still’s Disease, including Adult-Onset Still
label id: a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start: 1725

current approval status

not_reconciled

duplicate text group

dup-2cdd95830fe60f1a1fa9

extraction review status

automated_candidate_pending_source_review

generic names

CANAKINUMAB

ind-span-b9b4eb528dade81d2fef

label id

a09d3635-1735-4ac9-884e-5c49897da6f5

positive predicate support span

end: 1979
end exclusive: true
exact text: is indicated
label id: a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start: 1967

qualifier mentions

context exact
for the treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients.
kind
age
polarity
not_inferred
span
end
2044
end exclusive
true
exact text
adult
label id
a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start
2039
context exact
reatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients.
kind
age
polarity
not_inferred
span
end
2067
end exclusive
true
exact text
pediatric patients
label id
a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start
2049

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 2068
end exclusive: true
exact text: Familial Mediterranean Fever (FMF) ILARIS is indicated for the treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients.
label id: a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start: 1925

source url

https://api.fda.gov/drug/label.json?search=id%3A%22a09d3635-1735-4ac9-884e-5c49897da6f5%22

spl effective date

2026-06-08

spl set id

7d271f3b-e4f9-4d80-8dcf-28d49123f80e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 8 · positive indication candidate

application numbers

BLA125319

brand names

Ilaris

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2573
end exclusive: true
exact text: inase Deficiency (MKD) in adult and pediatric patients. Familial Mediterranean Fever (FMF) ILARIS is indicated for the treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients. 1.2 Still’s Disease (Adult-Onset Still’s Disease [AOSD] and Systemic Juvenile Idiopathic Arthritis [SJIA]) ILARIS is indicated for the treatment of active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older. 1.3 Gout Flares ILARIS is indicated for the symptomatic treatment of adult patients with gout flares in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not
label id: a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start: 1869

current approval status

not_reconciled

duplicate text group

dup-829b8960eafab0db0dd2

extraction review status

automated_candidate_pending_source_review

generic names

CANAKINUMAB

ind-span-8b94f8b0a9c45df94438

label id

a09d3635-1735-4ac9-884e-5c49897da6f5

positive predicate support span

end: 2195
end exclusive: true
exact text: is indicated
label id: a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start: 2183

qualifier mentions

context exact
1.2 Still’s Disease (Adult-Onset Still’s Disease [AOSD] and Systemic Juvenile Idiopath
kind
age
polarity
not_inferred
span
end
2095
end exclusive
true
exact text
Adult
label id
a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start
2090
context exact
ated for the treatment of active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopath
kind
age
polarity
not_inferred
span
end
2256
end exclusive
true
exact text
Adult
label id
a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start
2251
context exact
d Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older.
kind
age
polarity
not_inferred
span
end
2362
end exclusive
true
exact text
2 years of age
label id
a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start
2348

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 2373
end exclusive: true
exact text: 1.2 Still’s Disease (Adult-Onset Still’s Disease [AOSD] and Systemic Juvenile Idiopathic Arthritis [SJIA]) ILARIS is indicated for the treatment of active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older.
label id: a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start: 2069

source url

https://api.fda.gov/drug/label.json?search=id%3A%22a09d3635-1735-4ac9-884e-5c49897da6f5%22

spl effective date

2026-06-08

spl set id

7d271f3b-e4f9-4d80-8dcf-28d49123f80e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 9 · positive indication candidate

application numbers

BLA125319

brand names

Ilaris

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
positive_statement_also_contains_qualification_review_required

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2693
end exclusive: true
exact text: ) ILARIS is indicated for the treatment of active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older. 1.3 Gout Flares ILARIS is indicated for the symptomatic treatment of adult patients with gout flares in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.
label id: a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start: 2174

current approval status

not_reconciled

duplicate text group

dup-8cf1c6e6724e6ee77376

extraction review status

automated_candidate_pending_source_review

generic names

CANAKINUMAB

ind-span-3dc72afc0bcfc001323f

label id

a09d3635-1735-4ac9-884e-5c49897da6f5

positive predicate support span

end: 2409
end exclusive: true
exact text: is indicated
label id: a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start: 2397

qualifier mentions

context exact
Flares ILARIS is indicated for the symptomatic treatment of adult patients with gout flares in whom non-steroidal anti-inflammatory dr
kind
age
polarity
not_inferred
span
end
2457
end exclusive
true
exact text
adult patients
label id
a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start
2443

regulatory links

schema version

0.1.0

source batch sha256

424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3

source defined aliases

source span

end: 2693
end exclusive: true
exact text: 1.3 Gout Flares ILARIS is indicated for the symptomatic treatment of adult patients with gout flares in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.
label id: a09d3635-1735-4ac9-884e-5c49897da6f5
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: a5b9d58972af38761baf808c46d72b87038e13de80090a881c16dfa35d1c66f0
start: 2374

source url

https://api.fda.gov/drug/label.json?search=id%3A%22a09d3635-1735-4ac9-884e-5c49897da6f5%22

spl effective date

2026-06-08

spl set id

7d271f3b-e4f9-4d80-8dcf-28d49123f80e

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Preserved source evidence · Not medical advice